BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $10 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 82.7%

Neg 0% Neu 82.7% Pos 0%

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $10 price target.

Comments

No comments yet. Be the first!